PCSK9 and metabolic syndrome: RCT: Randomized controlled trial; Q2W: Every two weeks; QM: Monthly; LDL-C: Low-density lipoprotein cholesterol; MetS: Metabolic syndrome; NSTEMI: Non-ST-segment elevation myocardial infarction; PEP: Primary endpoint; RR: Incidence rate ratio; HR: Hazards ratio; FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk